PP_1170x120_10-25-21

Bristol Myers Squibb Co.

FDA approves Bristol Myers Squibb’s Zeposia

FDA approves Bristol Myers Squibb’s Zeposia

PRINCETON, N.J. — Bristol-Myers Squibb Co. announced Thursday that the U.S. Food and Drug Administration (FDA) approved Zeposia (ozanimod) 0.92 mg for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.  Zeposia, an oral medication taken once daily, is the only approved

Bristol Myers Squibb names Elizabeth Mily EVP

Bristol Myers Squibb names Elizabeth Mily EVP

NEW YORK — Bristol Myers Squibb Co. announced Wednesday that Elizabeth Mily has been appointed executive vice president, strategy and business development, effective March 30, 2020. In this role, Mily will oversee company strategy and all business development activities, including strategic partnerships, mergers and acquisitions, as well as other strategic initiatives. “Elizabeth is an accomplished

Adheris Health